Mesenchymal Stem Cell-Based Therapies against Podocyte Damage in Diabetic Nephropathy

• Published in: Tissue Engineering and Regenerative Medicine
• Main Author: Khalilpourfarshbafi M.; Hajiaghaalipour F.; Selvarajan K.K.; Adam A.
• Format: Review
• Language: English
• Published: Korean Tissue Engineering and Regenerative Medicine Society 2017
• Online Access: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85020393079&doi=10.1007%2fs13770-017-0026-5&partnerID=40&md5=6bf12ab5b3315b1e55cbb5ec12d5a752

Injury to podocytes is an early event in diabetic nephropathy leading to proteinuria with possible progression to end-stage renal failure. The podocytes are unique and highly specialized cells that cover the outer layer of kidney ultra-filtration barrier and play an important role in glomerular function. In the past few decades, adult stem cells, such as mesenchymal stem cells (MSCs) with a regenerative and differentiative capacity have been extensively used in cell-based therapies. In addition to their capability for regeneration and differentiation, MSCs contributes to their milieu by paracrine action of a series of growth factors via antiapoptotic, mitogenic and other cytokine actions that actively participate in treatment of podocyte damage through prevention of podocyte effacement, detachment and apoptosis. It is hoped that novel stem cell-based therapies will be developed in the future to prevent podocyte injury, thereby reducing the burden of kidney disease. © 2017, The Korean Tissue Engineering and Regenerative Medicine Society and Springer Science+Business Media Dordrecht.